OClawVPS.com
Cambridge Innovation Capital
Edit

Cambridge Innovation Capital

https://www.cic.vc
Last activity: 27.02.2026
Active
Invests in categories: InformationNewsTechnologyLegalTechDataPlatformHealthTechAIBioTechLearn
Cambridge Innovation Capital is a leading venture investor in Cambridge backing and building category-leading deep tech and life sciences companies. CIC currently manages over £275 million and has invested in 30+ companies.
CIC is also a preferred investor for the University of Cambridge, Europe’s top source of founders for venture-backed start-ups.
For more information visit www.cic.vc or follow @CambsInnovation
News
678
Portfolio
42
Mentions
80
Location: United Kingdom, England, Cambridge
Employees: 51-200
Founded date: 2013
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B

Portfolio 42

DateNameWebsiteTotal RaisedLocation
25.02.2026BeyondMathbeyondmath.com$27MUnited Kin...
30.05.2025Companiestrimtechtherapeutics.com$31MUnited Kin...
30.05.2025Companiessortera.bio--
26.12.2024Nucleranuclera.com$262.04MUnited Sta...
26.12.2024Forefront ...forefrontrf.com$31.24M-
18.05.2023Secondmindsecondmind.ai$16MUnited Kin...
18.05.2023AudioTelli...audiotelligence.com$12.54MUnited Kin...
18.05.2023Audio Anal...audioanalytic.com$17.5MUnited Kin...
18.05.2023Predict Im...predictimmune.com$25.2MUnited Kin...
18.05.2023Exvastatexvastat.com-United Kin...
Show more

News 678

DateTitleDescription
27.04.2023Complement Therapeutics appoints Dominic Moreland as Chief Financial OfficerComplement Therapeutics appoints Dominic Moreland as Chief Financial Officer Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the appoint...
24.04.2023Riverlane raises £15m Series B to advance useful quantum computingRiverlane raises £15m Series B to advance useful quantum computing Quantum engineering company Riverlane today announced it has raised £15 million in a Series B funding. The round was led by Molten Ventures and included participation from s...
17.04.2023Complement Therapeutics closes $79M A round for gene therapy in geographic atrophyComplement Therapeutics closes $79M A round for gene therapy in geographic atrophy BioWorld | By Cormac Sheridan Complement Therapeutics GmbH raised €72 million (US$79.4 million) in a series A round to move into the clinic a novel gene ther...
17.04.2023Cambridge Innovation Capital invests in Complement Therapeutics’ €72 Million Series A FundingCambridge Innovation Capital invests in Complement Therapeutics’ €72 Million Series A Funding Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has ...
17.04.2023VCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next yearVCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next year Endpoints News | By Kyle LaHucik, Associate Editor Complement Therapeutics raised a €72 million ($79.6 million) Series A to bankroll a Phase Ib of its ...
12.04.2023Microbiotica announces collaboration with MSD in a Phase 1b Clinical Trial in melanomaMicrobiotica announces clinical trial collaboration with MSD to evaluate MB097 in combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in melanoma Microbiotica, a leader in discovering and developing microbiome-based ther...
12.04.2023Pragmatic Semiconductor announces appointment of semiconductor industry veteran, David Moore, as CEOPragmatic Semiconductor announced today that its Board of Directors has appointed semiconductor industry veteran, David Moore, as Chief Executive Officer Moore will join Pragmatic with immediate effect and takes over from Pragmatic’s co-Fou...
07.04.2023UK’s Cambridge tries to catch up with younger, innovative peerUK’s Cambridge tries to catch up with younger, innovative peer New initiative aims to promote UK city on the world stage Kendall Square in Massachusetts is seen as a model for the UK Bloomberg UK | By Lisa Pham Home to one of the world’s ol...
05.04.2023We celebrate 10 years of ‘Science WOW’We celebrate 10 years of ‘Science WOW’ For the past ten years, Cambridge Science Centre has inspired over 500,000 children and young people with immersive STEM experiences and mind-blowing events. To kick off the festivities, Cambridge Scie...
04.04.2023Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEOOncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO Endpoints | Kyle LaHucik, Associate Editor The Wellcome Sanger Institute’s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the...
Show more

Mentions in press and media 80

DateTitleDescription
26.02.2026BeyondMath Secures $18.5M for Generative Physics AI ExpansionBeyondMath, a DeepTech leader, secured $18.5M in seed funding. This includes a $10M extension round. The company pioneers generative physics AI. It delivers engineering simulations 1000 times faster. This redefines design across aerospace, ...
25.02.2026BeyondMath secures $18.5M to expand its foundational physics AI modelLondon-based BeyondMath, a deeptech company that has developed a novel generative physics model, has raised a $10 million seed extension led by Cambridge Innovation Capital, with participation from existing investors including UP.Partners, ...
02.12.2025TRIMTECH Therapeutics appoints Alison Lawton as Chair of the BoardCambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment ...
18.11.2025T-Therapeutics Secures $91 Million to Advance Bispecific TherapiesT-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence. **T-Therapeutics Secures $91 Million to Advance Bis...
14.11.2025T-Therapeutics: Series A Extended To $91 Million As It Advances First-In-Class Bispecifics Toward The ClinicT-Therapeutics has expanded its Series A financing to a total of $91 million after securing an additional $32 million from new and existing investors. The Cambridge-based biotechnology company, which develops next-generation T cell receptor...
01.08.2025VC firm Cambridge Innovation Capital commits €115 million to back University of Cambridge spinoutsCambridge Innovation Capital (CIC), the VC firm investing in British high-potential DeepTech and life sciences companies, announced they are committing at least €115 million to invest in spinouts from the University of Cambridge. This inves...
28.05.2025BGF’s £3bn pledge offers hope amid concerns over UK competitivenessThe Business Growth Fund (BGF) has unveiled a £3bn commitment to back British businesses over the next five years which includes £500m earmarked for early stage start-ups in deep tech and life sciences. The organisation, which is one of the...
09.05.2025Deliveroo’s sale reignites fear over UK’s tech exodusWhen London-headquartered Deliveroo announced in early May that it had agreed to be acquired by US delivery giant Doordash, it triggered more than just a major shakeup in the food tech sector. To many in the industry, it was a familiar stor...
03.05.2025Cambridge GaN Devices – Closes $32m Series C funding roundWe are pleased to announce our latest investment in Cambridge GaN Devices (CGD), a University of Cambridge spinout developing energy-efficient semiconductors using gallium nitride (GaN), reshaping the future of power electronics. CGD’s tech...
10.03.2025Cambridge Innovation Capital: £100 Million Opportunity Fund ClosedCambridge Innovation Capital (CIC), a leading venture capital firm embedded in the Cambridge ecosystem, announced it has launched a new £100 million Opportunity Fund – which is anchored by Aviva Investors and British Patient Capital – to in...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In